Dianthus Therapeutics, Inc. /DE/ Income Statement
DNTH / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 10 fiscal years. All figures from audited SEC 10-K filings.
Dianthus Therapeutics, Inc. /DE/ reported $2M in revenue and $162M in net loss for FY2025. Revenue has declined at a 15.1% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | - | - | - | $0 | $0 | $0 | $0 |
| SG&A Expense | $34.3M | $25.0M | $18.2M | $6.7M | $27.9M | $28.1M | $23.8M | $18.6M | $7.8M | $3.5M |
| R&D Expense | $145.6M | $83.1M | $32.8M | $29.4M | $46.8M | $50.6M | $59.2M | $41.3M | $27.9M | $5.8M |
| Operating Income | -$177.9M | -$101.9M | -$48.2M | -$29.7M | -$74.7M | -$78.7M | -$83.0M | -$60.0M | -$35.7M | -$9.3M |
| Interest Expense | - | - | - | - | - | - | - | - | - | $163.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$162.3M | -$85.0M | -$43.6M | -$28.5M | -$71.1M | -$74.9M | -$76.8M | -$57.5M | -$35.5M | -$9.4M |
| EPS (Basic) | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 | -$1.71 | - | - | - | - |
| EPS (Diluted) | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 | -$1.71 | -$2.07 | -$65.15 | - | -$65.15 |
| Shares Outstanding | 43.2M | 31.1M | 5.2M | 874.2K | 54.9M | 43.9M | 39.3M | 2.4M | 1.9M | 149.4K |
| Operating Margin | -8739.3% | -1633.7% | - | - | - | - | - | - | - | - |
| Profit Margin | -7973.3% | -1362.8% | - | - | - | - | - | - | - | - |